SARS-CoV-2 infection is associated with anti-desmoglein 2 autoantibody detection
© The Author(s) 2023. Published by Oxford University Press on behalf of the British Society for Immunology..
Post-acute cardiac sequelae, following SARS-CoV-2 infection, are well recognized as complications of COVID-19. We have previously shown the persistence of autoantibodies against antigens in skin, muscle, and heart in individuals following severe COVID-19; the most common staining on skin tissue displayed an inter-cellular cement pattern consistent with antibodies against desmosomal proteins. Desmosomes play a critical role in maintaining the structural integrity of tissues. For this reason, we analyzed desmosomal protein levels and the presence of anti-desmoglein (DSG) 1, 2, and 3 antibodies in acute and convalescent sera from patients with COVID-19 of differing clinical severity. We find increased levels of DSG2 protein in sera from acute COVID-19 patients. Furthermore, we find that DSG2 autoantibody levels are increased significantly in convalescent sera following severe COVID-19 but not in hospitalized patients recovering from influenza infection or healthy controls. Levels of autoantibody in sera from patients with severe COVID-19 were comparable to levels in patients with non-COVID-19-associated cardiac disease, potentially identifying DSG2 autoantibodies as a novel biomarker for cardiac damage. To determine if there was any association between severe COVID-19 and DSG2, we stained post-mortem cardiac tissue from patients who died from COVID-19 infection. This confirmed DSG2 protein within the intercalated discs and disruption of the intercalated disc between cardiomyocytes in patients who died from COVID-19. Our results reveal the potential for DSG2 protein and autoimmunity to DSG2 to contribute to unexpected pathologies associated with COVID-19 infection.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:213 |
|---|---|
| Enthalten in: |
Clinical and experimental immunology - 213(2023), 2 vom: 21. Juli, Seite 243-251 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ward, Kerensa E [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Autoantibodies |
|---|
| Anmerkungen: |
Date Completed 24.07.2023 Date Revised 17.11.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/cei/uxad046 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM355992760 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM355992760 | ||
| 003 | DE-627 | ||
| 005 | 20231226065521.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/cei/uxad046 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1186.xml |
| 035 | |a (DE-627)NLM355992760 | ||
| 035 | |a (NLM)37095599 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ward, Kerensa E |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a SARS-CoV-2 infection is associated with anti-desmoglein 2 autoantibody detection |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 24.07.2023 | ||
| 500 | |a Date Revised 17.11.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2023. Published by Oxford University Press on behalf of the British Society for Immunology. | ||
| 520 | |a Post-acute cardiac sequelae, following SARS-CoV-2 infection, are well recognized as complications of COVID-19. We have previously shown the persistence of autoantibodies against antigens in skin, muscle, and heart in individuals following severe COVID-19; the most common staining on skin tissue displayed an inter-cellular cement pattern consistent with antibodies against desmosomal proteins. Desmosomes play a critical role in maintaining the structural integrity of tissues. For this reason, we analyzed desmosomal protein levels and the presence of anti-desmoglein (DSG) 1, 2, and 3 antibodies in acute and convalescent sera from patients with COVID-19 of differing clinical severity. We find increased levels of DSG2 protein in sera from acute COVID-19 patients. Furthermore, we find that DSG2 autoantibody levels are increased significantly in convalescent sera following severe COVID-19 but not in hospitalized patients recovering from influenza infection or healthy controls. Levels of autoantibody in sera from patients with severe COVID-19 were comparable to levels in patients with non-COVID-19-associated cardiac disease, potentially identifying DSG2 autoantibodies as a novel biomarker for cardiac damage. To determine if there was any association between severe COVID-19 and DSG2, we stained post-mortem cardiac tissue from patients who died from COVID-19 infection. This confirmed DSG2 protein within the intercalated discs and disruption of the intercalated disc between cardiomyocytes in patients who died from COVID-19. Our results reveal the potential for DSG2 protein and autoimmunity to DSG2 to contribute to unexpected pathologies associated with COVID-19 infection | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a autoantibodies | |
| 650 | 4 | |a autoimmunity | |
| 650 | 4 | |a infection | |
| 650 | 4 | |a virus | |
| 650 | 7 | |a Autoantibodies |2 NLM | |
| 700 | 1 | |a Steadman, Lora |e verfasserin |4 aut | |
| 700 | 1 | |a Karim, Abid R |e verfasserin |4 aut | |
| 700 | 1 | |a Reynolds, Gary M |e verfasserin |4 aut | |
| 700 | 1 | |a Pugh, Matthew |e verfasserin |4 aut | |
| 700 | 1 | |a Chua, Winnie |e verfasserin |4 aut | |
| 700 | 1 | |a Faustini, Sian E |e verfasserin |4 aut | |
| 700 | 1 | |a Veenith, Tonny |e verfasserin |4 aut | |
| 700 | 1 | |a Thwaites, Ryan S |e verfasserin |4 aut | |
| 700 | 1 | |a Openshaw, Peter J M |e verfasserin |4 aut | |
| 700 | 1 | |a Drayson, Mark T |e verfasserin |4 aut | |
| 700 | 1 | |a Shields, Adrian M |e verfasserin |4 aut | |
| 700 | 1 | |a Cunningham, Adam F |e verfasserin |4 aut | |
| 700 | 1 | |a Wraith, David C |e verfasserin |4 aut | |
| 700 | 1 | |a Richter, Alex G |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical and experimental immunology |d 1966 |g 213(2023), 2 vom: 21. Juli, Seite 243-251 |w (DE-627)NLM00001527X |x 1365-2249 |7 nnns |
| 773 | 1 | 8 | |g volume:213 |g year:2023 |g number:2 |g day:21 |g month:07 |g pages:243-251 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/cei/uxad046 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 213 |j 2023 |e 2 |b 21 |c 07 |h 243-251 | ||